A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at UC Davis UC Irvine UCLA UCSF
- Dates
- study startedestimated completion
- Principal Investigator
- by Bartosz Chmielowski (ucla)Samuel Ejadi (uci)Mehrdad Abedi, MD (ucdavis)David Oh, MD (ucsf)
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientists at UC Health
- Bartosz Chmielowski (ucla)
- Samuel Ejadi (uci)
- Mehrdad Abedi, MD (ucdavis)
Professor, Hematology and Oncology. Authored (or co-authored) 53 research publications. - David Oh, MD (ucsf)
I am a physician-scientist experienced in clinical and translational laboratory efforts to understand and improve upon cancer immunotherapies.
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- PACT Pharma, Inc.
- ID
- NCT03970382
- Phase
- Phase 1
- Study Type
- Interventional
- Last Updated